Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

27.98 -0.21 (-0.74%)

Streaming Delayed Price Updated: 9:57 AM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	102,560
Open	27.89
Bid (Size)	27.81 (100)
Ask (Size)	27.98 (100)
Prev. Close	28.19
Today's Range	27.58 - 28.10
52wk Range	25.52 - 40.87
Shares Outstanding	57,031,297
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Harmony Biosciences (HRMY) Earnings Transcript ↗

February 24, 2026

Harmony Biosciences (HRMY) Earnings Transcript

Via The Motley Fool

Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment ↗

February 24, 2026

Via Chartmill

Performance

YTD	-25.1%	-25.1%
1 Month	-25.1%	-25.1%
3 Month	-20.8%	-20.8%
6 Month	-24.7%	-24.7%
1 Year	-18.1%	-18.1%

More News

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

February 24, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick ↗

February 20, 2026

Via Chartmill

HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally ↗

February 17, 2026

Via Stocktwits

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment ↗

February 13, 2026

Via Chartmill

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

February 17, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity ↗

February 01, 2026

Via The Motley Fool

Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 ↗

January 31, 2026

Via The Motley Fool

Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup ↗

January 26, 2026

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy ↗

January 09, 2026

Via Chartmill

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 ↗

January 31, 2026

Via The Motley Fool

How Harmony Biosciences Can Prove Its Skeptics Wrong ↗

January 28, 2026

Via The Motley Fool

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? ↗

January 27, 2026

Via The Motley Fool

I Was Shocked to Find This Value-Priced Biotech Growth Stock ↗

January 26, 2026

Via The Motley Fool

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case ↗

January 06, 2026

Via Chartmill

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗

December 18, 2025

Via Chartmill

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

December 16, 2025

From Beacon Biosignals

Via GlobeNewswire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case ↗

December 12, 2025

Via Chartmill

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

December 08, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 02, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?

Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.

What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?

Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?

The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market

What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?

The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 27.98

When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?

The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 02/25/26 09:57 AM ET

What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?

The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.60B

How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?

Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.